on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Raises EUR 1.1 Million from Existing Shareholders
Paris-based biopharma company, GenSight Biologics, has successfully secured EUR 1.1 million in funding, backed by existing shareholders Heights Capital and Invus. The fundraising, completed without issuing a prospectus, mirrors similar financings from earlier in 2026. The proceeds will finance operational activities and support the Phase 3 RECOVER trial set for late March 2027.
The fundraising involved issuing ordinary shares and warrants. If exercised, these warrants could generate an additional EUR 0.93 million for the company. The structure of shares and pre-funded warrants aims to enhance shareholder value without preferential rights. Following the fundraising, GenSight's capital structure sees Invus and Heights Capital holding significant shares.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news